Osteoprotegerin inhibits the development of osteolytic bone disease in multiple myeloma.

Multiple myeloma is a B-cell malignancy characterized by the accumulation of plasma cells in the bone marrow and the development of osteolytic bone disease. The present study demonstrates that myeloma cells express the critical osteoclastogenic factor RANKL (the ligand for receptor activator of NF-k...

Cijeli opis

Bibliografski detalji
Glavni autori:	Croucher, P, Shipman, C, Lippitt, J, Perry, M, Asosingh, K, Hijzen, A, Brabbs, A, van Beek, E, Holen, I, Skerry, T, Dunstan, C, Russell, G, Van Camp, B, Vanderkerken, K
Format:	Journal article
Jezik:	English
Izdano:	2001

Osteoprotegerin inhibits the development of osteolytic bone disease in multiple myeloma od Croucher, P, Shipman, C, Perry, M, Lippitt, J, Asosingh, K, van Beek, E, Van Camp, B, Russell, R, Dunstan, C, Vanderkerken, K

Izdano 2001

Journal article

Osteoprotegerin inhibits the development of osteolytic bone disease in multiple myeloma.

Osteoprotegerin inhibits the development of osteolytic bone disease in multiple myeloma od Croucher, P, Shipman, C, Perry, M, Lippitt, J, Asosingh, K, van Beek, E, Van Camp, B, Russell, R, Dunstan, C, Vanderkerken, K

Slični predmeti